ziptides semaglutide Compounded Kit Zepbound outperforms Ozempic and Wegovy
Description
The FDA prescribing information does not mandate a gradual dose reduction protocol when stopping treatment
It is unaffected by variables such as pH, food intake, and intestinal environment
Unmonitored use opens the door to misuse and complications
Ban K, Kim H, Cho J et al (2010) GLP-1(9-36) protects cardiomyocytes and endothelial cells from ischemia-reperfusion injury via cytoprotective pathways independent of the GLP-1 receptor
